Literature DB >> 6974335

Management of severe postpartum hemorrhage due to uterine atony using an analogue of prostaglandin F2 alpha.

R H Hayashi, M S Castillo, M L Noah.   

Abstract

Twenty patients with severe postpartum hemorrhage due to uterine atony who were unresponsive to conventional therapy were treated with 0.25-mg intramuscular injections of (15-S)-15-methyl prostaglandin F2 alpha-tromethamine. A rapid and successful response was obtained in 18 patients. Two patients required surgical procedures to control bleeding. Both patients with treatment failure had chorioamnionitis. Side effects of the prostaglandin therapy included nausea, vomiting and diarrhea, a transient mild temperature elevation, and a transient moderate blood pressure elevation. Those subjects with preeclampsia did not demonstrate a serious elevation of blood pressure. The prostaglandin F2 alpha analogue appears to be very effective in the treatment of postpartum hemorrhage due to uterine atony.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974335

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Prostaglandins--lifesaving drugs for postpartum uterine atony.

Authors:  V A Catanzarite
Journal:  West J Med       Date:  1986-04

2.  Remifentanil for Carboprost-Induced Adverse Reactions During Cesarean Delivery Under Combined Spinal-Epidural Anesthesia.

Authors:  Chang-Na Wei; Xiang-Yang Chang; Jin-Hua Dong; Qing-He Zhou
Journal:  Front Pharmacol       Date:  2020-06-30       Impact factor: 5.810

3.  The development of oxytocic drugs in the management of postpartum haemorrhage.

Authors:  Thomas F Baskett
Journal:  Ulster Med J       Date:  2004-05

4.  Route of oxytocin administration for preventing blood loss at caesarean section: a systematic review with meta-analysis.

Authors:  Maria Regina Torloni; Monica Siaulys; Rachel Riera; Ana Luiza Cabrera Martimbianco; Rafael Leite Pacheco; Carolina de Oliveira Cruz Latorraca; Mariana Widmer; Ana Pilar Betran
Journal:  BMJ Open       Date:  2021-09-16       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.